




The relative strengths and weaknesses of Enanta Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enanta Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 166% points. The greatest weakness of Enanta Pharmaceuticals INC is the variable Assets, reducing the Economic Capital Ratio by 2.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 472%, being 218% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	107,975
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,746
Liabilities, Non-Current	229
Other Assets	45,637
Other Compr. Net Income	-98
Other Expenses	-15,170
Other Liabilities	1,786
Other Net Income	283
Other Revenues	47,741
Property and Equipment	1,803
Research and Development	18,740
Selling, General and Administrative Expense	10,016

Output Variable	Value in 1000 USD
Assets	155,415
Liabilities	6,761
Expenses	13,586
Revenues	47,741
Stockholders Equity	148,654
Net Income	34,438
Comprehensive Net Income	34,389
BaseVar	111,942
ECR before Limited Liability	442%
Economic Capital Ratio	472%